Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204)

MLA

Sara A. Hurvitz, et al. “Abstract OT1-14-01: Zanidatamab in Combination with ALX148 in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Cancers, Including Breast Cancer: A Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204).” Cancer Research, vol. 82, Feb. 2022, pp. OT1-14. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs21-ot1-14-01.

APA

Sara A. Hurvitz, Jorge Chaves, Adam Brufsky, Alberto J. Montero, Bruno Fang, Kay Yeung, Manish R. Patel, Ritesh Parajuli, Adam Omidpanah, Elaina Gartner, Abraham Fong, Sophia Randolph, & Funda Meric-Bernstam. (2022). Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204). Cancer Research, 82, OT1-14. https://doi.org/10.1158/1538-7445.sabcs21-ot1-14-01

Chicago

Sara A. Hurvitz, Jorge Chaves, Adam Brufsky, Alberto J. Montero, Bruno Fang, Kay Yeung, Manish R. Patel, et al. 2022. “Abstract OT1-14-01: Zanidatamab in Combination with ALX148 in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Cancers, Including Breast Cancer: A Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204).” Cancer Research 82 (February): OT1-14. doi:10.1158/1538-7445.sabcs21-ot1-14-01.